



1




2




3



4



5



6

Benefits of an Early and Accurate Diagnosis



Medical Benefits

- Access to current treatments
- An opportunity to participate in clinical trials
- A chance to prioritize health, including making lifestyle changes



Emotional and Social Benefits

- More time to plan for the future, access resources
- Time to plan end-of-life decisions



Financial Benefits


- Cost savings for families
- Cost savings for the U.S. government

ALZHEIMER'S ASSOCIATION

7

How is Alzheimer's Currently Diagnosed?

There is no single test that can determine if a person is living with Alzheimer's disease or another dementia. Doctors use a combination of diagnostic tools combined with medical history to make an accurate diagnosis.




ALZHEIMER'S ASSOCIATION

8

What is a Biomarker?

A biomarker is a biological marker that measures change.



Biomarkers are reliable predictors and indicators of disease and disease progression.

For example:

- Glucose is a biomarker for insulin resistance and diabetes.
- Cholesterol is a biomarker for heart disease

Uses of biomarkers in Alzheimer's disease include:

Diagnostic: used to determine diagnosis

Enrichment: used to determine entry into a clinical trial

Prognostic: used to determine course of illness

Predictive: used to track outcomes and side effects of treatments

ALZHEIMER'S ASSOCIATION

9

Biomarkers

A New Frontier in Alzheimer's Detection, Diagnosis and Research

Cerebrospinal fluid (CSF) analysis can be used to detect amyloid in the CSF (taken by a lumbar puncture), which can be predictive of changes in the brain.

There are several emerging **blood tests** on the market that can indicate presence of Alzheimer's markers years before symptoms emerge.

Blood tests for Alzheimer's should be prescribed by a doctor and followed by other methods of diagnosis.



Positron emission tomography (PET) scan results aid doctors in diagnosing and treating memory conditions. There are FDA approved PET scans that measure amyloid and tau.

Magnetic Resonance Imaging (MRI) can help doctors rule out other symptoms that may be causing dementia symptoms, as well as track treatment side effects.

Other **emerging biomarkers** include:

- examining skin and saliva to indicate early biological changes in the brain
- retinal imaging which show promise to be low cost, accessible detection methods for Alzheimer's.

ALZHEIMER'S ASSOCIATION

10

Treatment

ALZHEIMER'S ASSOCIATION

11


FDA-Approved Therapies for Alzheimer's

First description of disease 1906	Treat Symptoms: Cognition and Function		Treat Symptoms: Mood or Behavior		Slow Disease Progression: Cognition, Function and Behavior	
	Asymptomatic	MCI	Mild Dementia	Moderate Dementia	Severe Dementia	
1996	donepezil (Aricept)					
2000	rivastigmine (Exelon)					
2001	galantamine (Razadyne)					
2003	memantine (Namenda)					
2014	memantine + donepezil (Namzaric)					
2020	suvorexant* (Belsomra)					
2021	aducanumab (Aduhelm)					
2023	lecanemab (Leqembi)					
2023	brexpiprazole (Rexulti)					
2024	donanemab (Kisunla)					

* Suvorexant approved for insomnia not AD but safe and effective in AD population.

ALZHEIMER'S ASSOCIATION


12




13



14



15



16

U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk

U.S. POINTER
ALZHEIMER'S ASSOCIATION

Two Year | Multi-Center (Five U.S. Sites) | Randomized Clinical Trial
2,000 Participants | 60-79 Years Old | At Risk for Cognitive Decline

Self-Guided and Structured Intervention Groups
Physical Activity | Nutrition | Intellectual Engagement | Health Coaching
Differ in Format, Expectations, and Accountability

Commitment to Community-Based Outreach, Recruitment and Representation

- ✓ Completed Recruitment in March 2023
- ✓ ~ 30% from Underrepresented Populations

NIA Supported Ancillary Studies:

- ✓ POINTER-Neuroimaging
- ✓ POINTER-zzz
- ✓ POINTER-Neurovascular
- ✓ POINTER-Microbiome

If the interventions prove effective, this study will lead the way in the development of an accessible and sustainable community-based program for prevention.

ALZHEIMER'S ASSOCIATION

17



18




19



20



21



22